The metabolic fate of a compound can often determine the success of a new drug lead.
Introduction
Liquid chromatography mass spectrometry (LCMS) is widely used for detecting and identifying drug metabolites at trace levels in extremely complicated biological fluids that can contain thousands of endogenous compounds. 1 For metabolites that are unknown and unexpected, it can be challenging to determine which of the thousands of ions detected in an LCMS experiment correspond to the downstream metabolites of precursor compounds. This "needle-in-a-haystack" problem requires the development of methods to rapidly identify the products of compounds in complex mixtures, at trace levels, and without prior knowledge about the identity of the metabolites.
An elegant approach to the rapid non-targeted identification of drug metabolites was demonstrated in the early 1970s by Knapp et al. who simultaneously administered a 1:1 mixture of nortriptyline and [ 2 H3]-nortriptyline to human subjects and then analysed urine samples using gas chromatography mass spectrometry (GCMS). 2 They observed that metabolites of nortriptyline which retained the isotopic label eluted from the GC column at the same time and with the same abundance as those derived from the unlabelled drug, but the masses of the labelled and unlabelled metabolite ions differed in the mass spectra by a precisely known amount due to the isotopic label. These 'twin-ions' provide a signature in the GCMS or LCMS data that is unique to drug metabolites so that they can be distinguished from the multitude of endogenous compounds in a non-targeted manner; that is, without authentic standards or any information about the identity of the metabolites. Despite the obvious practical advantages of non-targeted twin-ion metabolite detection, the use of this method has been limited 3 partly because (i) the resolution of many types of common mass spectrometers were insufficient to detect low abundance metabolite ions, and (ii) it was challenging to identify twin-ion metabolite signatures in large data sets. 4 Given the significant advances in mass spectrometer performance, there has been renewed interest in using the twin ion method for a range of biological applications including the identification of trace level metabolites of insecticides in susceptible insects in vivo, 5 the determination of pharmacokinetic parameters such as bioavailability 6 and the elucidation of metabolic pathways and mechanisms. 3a Due to the number of ions that can be detected in high resolution LCMS experiments, it is important that twin-ion metabolite identification is automated to alleviate the laborious and inefficient task of manually searching through such datasets. Several computer algorithms have been developed to identify twin-ion metabolite doublets in LCMS data. 7 For example, MetExtract developed by Schumacher and coworkers 7f initially considers each data point in each mass spectrum to be the unlabelled metabolite and the algorithm then searches for a theoretical peak at a higher m/z containing a defined number of isotopic labels. A twin-ion "hit" is assigned if this peak is found at a comparable intensity to the unlabelled peak. However, all existing programs (to our knowledge) for automated twin ion detection of unknown isotope labelled metabolite ions are optimized for datasets that have been "centroided," in which the number of data points corresponding to a given ion is reduced to a single point. While this significantly reduces the computational cost for identifying the twin-ion peaks, centroiding can increase the signal-tonoise (S/N) that is required to confidently detect a given ion. Ideally, all data reduction steps should be eliminated to enable trace level metabolites to be reliably detected.
Here, we demonstrate a non-targeted approach to detecting drug metabolites that combines the twin ion method with automated data-mining software for non-targeted identification of drug metabolites. We have selected acetaminophen (APAP), a clinically relevant and widely used analgesic, to test this approach because it has a metabolic profile that is well established. By eliminating centroiding, the number of APAP metabolites that can be detected in plasma extracts from rats (therapeutic dose) by a custom program entitled High-resolution Twin Ion Metabolite Extraction (HiTIME) increased by nearly a factor of 2.
Experiments
A 1:1 mixture of APAP: 13 C6-APAP (5 mg kg -1 of each isotopomer; ca. therapeutic dose) was administered intravenously to adult male Sprague-Dawley rats (327-366 g; isoflurane anaesthetized). Blood samples were drawn after 30 min. Blood plasma was prepared by addition of methanol to precipitate proteins and analysed using an Agilent 1100 LC coupled to an Agilent 6520-B Quadrupole-Time-of-Flight MS over a 67 min water/acetonitrile solvent gradient in both positive and negative ion polarities. Full details of the experiments and the HiTIME algorithm are in supporting information.
Results and Discussion

Positive ion mode LCMS analysis of extracts of blood plasma obtained from rats exposed to a saline solution that contained 10 mg kg -1 of 1:1 ratio of APAP and [ 13 C6]-APAP resulted in the detection of 4957 and 2128 peaks in the respective positive and negative ionization modes (mass-spectral intensity threshold of 500 ion counts; average of n = 3 separate rats) that can be identified by standard algorithms using the native Agilent software.
Unknown/unexpected metabolite ions can be identified by use of a mass defect filter 8 to identify metabolites based on well-defined shifts in the differences between the accurate and integer m/z values. By use of a 50 mDa filter, which is sufficiently wide to cover many phase I and II metabolic transformations, 8 an average of 1567 and 1460 peaks for positive and negative ionization modes were respectively identified, which presents a challenge for metabolite identification.
To identify twin-ion signatures, a custom computer program was designed to automatically search through LCMS data and highlight data segments wherein the "twin-ion" metabolite ions are observed. For example, in Figure 1a HiTIME searches for twin-ion pairs that are defined as having: (i) identical retentions times for the heavy and light isotopomers (i.e., for the precursor ions in Figure 1a , the retention times of each ion is 13.1 min); (ii) identical abundances for the heavy and light isotopomers;
and (iii) a difference in m/z values that corresponds to the known mass difference between heavy and light isotopomers (the labelled and unlabelled APAP ions differ by 6.0201 m/z, theoretical value: 6.0201).
For HiTIME, each LCMS data point is weighted based on the goodness-of-fit to an idealised twin ion shape. Such a shape is approximated by two 3-dimensional Gaussian surfaces (retention time, m/z value, and ion abundance are the x, y and z coordinates, respectively) that are centered at the retention time and m/z value of the data point of interest, spaced by the mass difference between heavy and light isotopes (6.0201 Da) , and have the same widths and heights (Figures 1b and S1 ). To test for an ideal twin ion 'hit,' the absolute heights and widths of both Gaussian distributions are optimised (and keeping the ratios between the widths and heights of each distribution constant). Each LCMS data point is assigned a confidence score that indicates how well the twin-ion model centered at that point fits the surrounding data (Figure 1c) . The results can then be visualised as a heat map that depicts both mass spectral and chromatographic domains with confidence scores that are indicated by a colour gradient (Figure 1d) . To facilitate the identification of ions detected in trace abundances, the HiTIME algorithm does not consider absolute peak intensity when assigning confidence scores to a data point; i.e. a low-abundance twin-ion should be assigned the same score as that for a high abundance twin ion (in the absence of other factors) .
Applying this algorithm to the negative ion LCMS data from the blood plasma of acetaminophen treated rats generates the heat map shown in Figure S2a . Numerous 'bright spots' are seen that are assigned weighted intensities of >5 indicating a strong correlation between the data in these regions and the model twin-ion signature. These signals likely arise from the elution of isotopically labelled drug metabolites. However, endogenous compounds unrelated to one another may by chance give an LCMS profile similar to that of the twin-ion signature. Cumulative intensity histograms depicting the distribution of weighted values are shown in Figure S3 . 80% of the data in the raw files (representing tens of thousands of data points) are assigned a very low confidence value (<2). On this basis, data points assigned a weighted intensity value of <2 are considered to have negligible correlation to the twin-ion model and are excluded from the plots shown here. Endogenous compounds can be discounted by comparing the treatment sample against the control sample shown in Figure   S2b . Corresponding bright spots are absent in the heat map generated from control LCMS experiments on blood drawn prior to APAP dosing. To remove these interferences, the control data were subtracted from those produced following APAP treatment and the results are shown in Figure 2 . White space in the plots indicates a score of 2 (or less) meaning that essentially no correlation is observed between the hypothetical twin ion model and the raw data (>99.7% of all data points). This indicates that the vast majority of the data does not match the expected APAP metabolite twin ion profile and has been removed by the HiTIME algorithm.
For some of the highly scoring regions in Figure 2 , multiple high scoring data points are identified at the same retention time but at different m/z values. These are not observed in the control data and, based on high-resolution mass measurements and isotope distributions, arise from simple non-covalent adducts between twin-ion metabolites and inorganic salts (e.g., [M+Na] + and [M+H+NaHCO2] + ) or other endogenous products that are commonly formed in the ESI process ( Table S1 ). As it is highly unlikely that unrelated endogenous compounds would produce this phenomenon simply by chance (based on the control data;
FigureS2b), such adduct ions can provide additional confirmation that a metabolite was detected.
Analysing the subtracted heat maps, a total of 9 unique highly scoring regions were identified that had a unique retention time and a weighted intensity greater than 5 in either positive or negative background subtracted data sets (Figure 2) . The 9 regions were manually investigated by plotting extracted ion chromatograms (EICs for both the heavy and light isotopes of potential metabolites using m/z values obtained for ions that were assigned a high confidence value in the Figure 2 data. In this way, the presence of APAP metabolites could be readily verified by searching for regions where the EIC traces for heavy and light isotopes of suspected metabolites overlap.
To demonstrate for a particularly low abundance metabolite, the twin ion signature for the rarely reported APAP metabolite, 3-methoxyacetaminophen-4-sulphate (APAP-OMe-SO3), is detected at m/z 260 and m/z 266 in the negative ion mode (Figure 3) . The EIC traces of each ion closely overlap for t = 12.86 min (Figure 3 inset) , which is indicative of a twinion hit. For the vehicle control data, the analogous twin ions were not observed (Figure 3 , inset). The accurate m/z difference between 13 C6-APAP-OMe-SO3 and APAP-OMe-SO3 is 6.0230 (within 11 ppm of the ideal value of 6.0201), and the abundances of these ions are essentially identical. In this case the mass spectral peak for the unlabelled isotope of APAPOMe-SO3 (m/z 260.0238, marked in Figure 3 with a red arrow) is immediately adjacent to an endogenous compound at m/z 260.1318.
In total, 9 acetaminophen metabolites were identified by use of HiTIME and confirmed by plotting the EICs of the heavy and light isotopomers. The APAP metabolites that were identified are listed in Table 1 and their structures and nomenclature are shown in The twin ion signature that corresponds to APAP-OMe-SO3 (Figure 3 ) is representative of a low abundance metabolite ion that was identified by use of HiTIME. Of the 9 acetaminophen metabolites identified in this study, 5 were detected at ca. 10 3 ion counts, which is close to the mass-spectral intensity threshold of 500 ion counts. If the identity of these metabolites were not known in advance, it would be challenging to identify and assign these low abundance twin-ion signals. Overall, these data indicate that HiTIME can identify twin-ion signatures even at relatively low S/N values (> ca. 10).
To rule out the possibility of "false-negatives" being assigned by the HiTIME algorithm (i.e., low confidence scores assigned to actual acetaminophen metabolites showing the twin-ion signature), a list of all reported metabolites of APAP and the related compound (and known APAP metabolite) 4-aminophenol was assembled from literature sources (31 metabolites in total, see Supporting Information for references) and their corresponding m/z values for the heavy and light isotopes. 9 EIC traces were plotted for each potential twin ion that was not already assigned by the HiTIME algorithm. In no case was a region of clear overlap between the EIC traces of heavy and light isotopomers observed. These data provide confidence that HiTIME has accurately assigned all known metabolites of APAP that were present in the plasma samples, ionized, resolved and detected.
While the abundances of the 9 metabolites detected here vary considerably in the raw LCMS data, they are assigned similar confidence scores after weighting with the HiTIME algorithm. For example, APAP-CYS is detected with only a very low abundance (integrated peak area = 63186, Table 1 ) and is assigned a weighted intensity of 9.4 by the HiTIME algorithm. By contrast the precursor compound, APAP, was detected in high abundance (peak area = 13942546) that is ca. 200 fold greater than that for APAP-CYS and is assigned the same weighted intensity value of 9.4. These data demonstrate that the HiTIME algorithm can provide a non-targeted and unbiased assessment of twin-ion signatures present in a sample for a wide range of ion abundances.
To benchmark HiTIME, we compared our results to those generated by processing the same dataset with the freely available MetExtract software, which is also designed to identify twin-ion signatures in LCMS data. 7f As MetExtract is optimized for the interpretation of LCMS data in the 'centroided' format, our raw, profile data were centroided with the commonly used application MSConvert 10 and these data were manually inspected to ensure that the signals for these metabolites were preserved throughout the data formatting process.
MetExtract correctly identified 5 of the 9 twin-ion signatures known to be present in the data set, however there were 4 metabolites that were not identified (APAP-GSH, APAP-CYS, APAP-OH-SO3 and APAP-OMe-SO3). By use of an m/z tolerance of 99 ppm (the maximum allowed value by MetExtract) and the ion doublet intensity ratio threshold was set to 0.5, one additional metabolite (APAP-CYS) was identified.
The discrepancy between the numbers of twin ion signatures that were identified may result from a detrimental impact of centroiding on (i) signal-to-noise ratio, and/or (ii) mass accuracy. Figure S4 shows a plot of the ratio between profile S/N and centroid S/N as a function of signal intensity. Profile S/N is routinely 2-3 times higher than that for centroided data and is largely independent of signal intensity. In addition, the four metabolites that were not identified in centroid mode were detected in the lowest abundance. The absolute m/z accuracy values (in ppm) between the labelled and unlabelled twin ions (ideal: 6.0201 Da) tend to be slightly higher for profile (average of 4.2 ppm) than for centroid data (average of 6.4 ppm; Figure S5 ), which indicates that centroiding can have a detrimental effect on mass accuracy. Both effects could result in the identification of fewer twin ion signatures in the centroided data than the profile data. Overall, these results indicate that by using HiTIME, in which high-resolution mass spectral data are directly processed without data reduction (i.e., peak centroiding), a significantly larger number of metabolites can be identified in these experiments.
Conclusion
An automated process for the non-targeted detection of drug metabolites was demonstrated for the detection of APAP metabolites in blood plasma taken from rats that were administered a 1:1 mixture of APAP and [ 13 C6]-APAP. The HiTIME algorithm successfully identified a series of doublet signals in unprocessed LCMS data that correspond to 9 metabolites of acetaminophen, including 3 which are important indicators of acetaminophen bioactivation and 4 that are rarely reported. The combination of isotopic labelling, LCMS, and the direct high performance computational processing of high resolution mass spectral data files without data reduction enabled all APAP metabolites to be rapidly and comprehensively identified in complex biological mixtures in a non-targeted and unbiased approach. By eliminating peak centroiding, which can lower S/N values and m/z accuracy, lower abundance ions can be identified more readily in complex mixtures.
Although this can increase computational cost, the use of HiTIME should benefit many LCMS measurements for the identification and detection of the downstream metabolites of analytes in complex mixtures. HiTIME has been made freely available on the World Wide Web (https://github.com/bjpop/HiTIME).
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